Most ‘GLP-1 Nonresponders’ Never Get a Fair Shot
I see this pattern every week. A patient is 12 weeks into semaglutide therapy. They’ve lost 2%-3% of…
Orforglipron Helps Maintain Weight Loss After Injectables
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 receptor agonist, helps people maintain…